Dolapcioglu, KenanDogruer, GokhanOzsoy, SuleErgun, YasarCiftci, SinasiKarapinar, Oya SoyluAslan, Erdogan2024-09-182024-09-1820130301-21151872-7654https://doi.org/10.1016/j.ejogrb.2013.05.026https://hdl.handle.net/20.500.12483/9789Objectives: The aim of this study was to compare the effects of theranekron, medroxyprogesterone acetate (MPA), and leuprolide acetate (LA) on surgically induced endometriosis in a rat model. Study design: Endometriosis was surgically induced in forty female rats during estrus. After 3 weeks, a second operation was performed and the rats were randomized using a randomization table into theranekron, MPA, LA, and control groups. These treatments were continued for 3 weeks. A third operation was performed to evaluate treatment results. Then, the experimental treatments were halted and estrogen was initiated again to maintain estrus. After three additional weeks; i.e. after 9 weeks, the recurrence rate of endometrial foci was evaluated in a fourth operation and the rats were sacrificed. The volume of endometriotic foci and histopathology scores before and after treatment were compared. Results: The respective mean volumes of the endometriotic foci after 3, 6, and 9 weeks were 86.4 +/- 21.2, 16.4 +/- 8.2, and 20.1 +/- 9.6 mm(3) in the theranekron group, 78.3 +/- 20.4, 42.6 +/- 13.5, and 66.7 +/- 16.2 mm(3) in the MPA group, and 91.8 +/- 30.2, 34.4 +/- 11.4, and 72.4 +/- 21.9 mm(3) in the LA group. The respective mean histopathology scores were 2.4 +/- 0.6, 1.8 +/- 0.6, and 1.6 +/- 0.6 in the theranekron group, 2.5 +/- 0.8, 2.0 +/- 1.1, and 2.7 +/- 1.0 in the MPA group, and 2.3 +/- 0.5, 2.1 +/- 1.2, 2.4 +/- 0.8 in the LA group. After 9 weeks, the mean volume of endometriotic foci and histopathology scores were significantly lower in the theranekron group. Conclusions: Theranekron caused more evident regression of endometriotic foci than MPA or LA in a rat model. After stopping the theranekron treatment, the recurrence rate was also lower than that of the other groups. (C) 2013 Elsevier Ireland Ltd. All rights reserved.eninfo:eu-repo/semantics/closedAccessEndometriosisRat modelTheranekronMedroxyprogesteroneLeuprolideArticle170120621010.1016/j.ejogrb.2013.05.026238276902-s2.0-84883052185Q2WOS:000325122000040Q3